Lactococcus lactis-based vaccines Current status and future perspectives

被引：20
作者：
Bahey-El-Din, Mohammed [1 ,2 ,3 ,4 ]
Gahan, Cormac G. M. [1 ,2 ,3 ]
机构：
[1] Univ Coll Cork, Dept Microbiol, Cork, Ireland
[2] Univ Coll Cork, Sch Pharm, Cork, Ireland
[3] Univ Coll Cork, Alimentary Pharmabiot Ctr, Cork, Ireland
[4] Univ Alexandria, Fac Pharm, Dept Pharmaceut Microbiol, Alexandria, Egypt
来源：
HUMAN VACCINES | 2011年 / 7卷 / 01期
关键词：
Lactococcus lactis; vaccine delivery; GEM; biological containment; COMPLETE GENOME SEQUENCE; MUCOSAL DELIVERY; MURINE INTERLEUKIN-2; ORAL IMMUNIZATION; ESCHERICHIA-COLI; PROTECTION; ANTIGEN; IMMUNOGENICITY; RESPONSES; TETANUS;
D O I：
10.4161/hv.7.1.13631
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Lactococcus lactis offers significant potential as a platform for the delivery of vaccines especially via mucosal routes of administration. The organism has an established history of safe use in the food industry and is highly amenable to genetic manipulation, with many systems available for efficient production of secreted and surface-expressed proteins. Here we describe the benefits of using this organism as a vaccine delivery platform and outline how L. lactis based antigen delivery may be improved. Finally we discuss the safe use of L. lactis vectors and outline the potential for use of biological containment systems and killed lactococcal preparations.
引用
收藏
页码：106 / 109
页数：4
相关论文
共 36 条
[1]   Thymine metabolism and thymineless death in prokaryotes and eukaryotes [J].
Ahmad, SI ;
Kirk, SH ;
Eisenstark, A .
ANNUAL REVIEW OF MICROBIOLOGY, 1998, 52 :591-625
[2]   Development of lactococcal GEM-based pneumococcal vaccines [J].
Audouy, Sandrine A. L. ;
van Selm, Saskia ;
van Roosmalen, Maarten L. ;
Post, Eduard ;
Kanninga, Rolf ;
Neef, Jolanda ;
Estevao, Silvia ;
Nieuwenhuis, Edward E. S. ;
Adrian, Peter V. ;
Leenhouts, Kees ;
Hermans, Peter W. M. .
VACCINE, 2007, 25 (13) :2497-2506
[3]   Lactococcus lactis-expressing listeriolysin O (LLO) provides protection and specific CD8+ T cells against Listeria monocytogenes in the murine infection model [J].
Bahey-El-Din, Mohammed ;
Casey, Pat G. ;
Griffin, Brendan T. ;
Gahan, Cormac G. M. .
VACCINE, 2008, 26 (41) :5304-5314
[4]  
Bahey-El-Din Mohammed, 2010, Bioeng Bugs, V1, P66, DOI 10.4161/bbug.1.1.10284
[5]   Lactococcus lactis as a Cell Factory for Delivery of Therapeutic Proteins [J].
Bahey-El-Din, Mohammed ;
Gahan, Cormac G. M. ;
Griffin, Brendan T. .
CURRENT GENE THERAPY, 2010, 10 (01) :34-45
[6]   Intranasal immunization with recombinant Lactococcus lactis secreting murine interleukin-12 enhances antigen-specific Th1 cytokine production [J].
Bermúdez-Humarán, LG ;
Langella, P ;
Cortes-Perez, NG ;
Gruss, A ;
Tamez-Guerra, RS ;
Oliveira, SC ;
Saucedo-Cardenas, O ;
de Oca-Luna, RM ;
Le Loir, Y .
INFECTION AND IMMUNITY, 2003, 71 (04) :1887-1896
[7]   Production of human papillomavirus type 16 E7 protein in Lactococcus lactis [J].
Bermúdez-Humarán, LG ;
Langella, P ;
Miyoshi, A ;
Gruss, A ;
Guerra, RT ;
de Oca-Luna, RM ;
Le Loir, Y .
APPLIED AND ENVIRONMENTAL MICROBIOLOGY, 2002, 68 (02) :917-922
[8]   The complete genome sequence of Escherichia coli K-12 [J].
Blattner, FR ;
Plunkett, G ;
Bloch, CA ;
Perna, NT ;
Burland, V ;
Riley, M ;
ColladoVides, J ;
Glasner, JD ;
Rode, CK ;
Mayhew, GF ;
Gregor, J ;
Davis, NW ;
Kirkpatrick, HA ;
Goeden, MA ;
Rose, DJ ;
Mau, B ;
Shao, Y .
SCIENCE, 1997, 277 (5331) :1453-+
[9]  
CHALLACOMBE SJ, 1992, IMMUNOLOGY, V76, P164
[10]   STUDIES ON UNBALANCED GROWTH IN ESCHERICHIA-COLI [J].
COHEN, SS ;
BARNER, HD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1954, 40 (10) :885-893
1234